Skip to main content
Equibles
PBLS logo

PBLS · Parabilis Medicines, Inc.

Track PBLS — free

Use PBLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PBLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$30.55 -1.74 (-5.39%)
Russell 2000 member Rebalance outlook locked
Market Cap
$3.85B
Shares
123.53M
Volume · Oct 1 885.86K Avg daily vol (3M) 640.73K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.29 Open$31.95 Day$31.20–32.86 Available close range$25.01–41.73 Avg vol 30d898K Short int6.1M · 4.9% float · 13.3d Short vol84% DataJun 2026–Sep 2026 Filing10-Q · Aug 13

The closing range uses available history since Jun 10, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.11B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,331.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.9%
Latest settlement · 13.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −11%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 44%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+79 funds added
Insider flow Accumulating
Net +$6.9M over 90 days · 0% sells
Short interest Rising
4.93% of float · ▲ +10.4% MoM · 13.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
79 holders — 13F breadth
Squeeze score 70
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −25%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−11% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
44% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+79 funds added
Insider flow Accumulating
Net +$6.9M over 90 days · 0% sells
Short interest Rising
4.93% of float · ▲ +10.4% MoM · 13.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
79 holders — 13F breadth
Price context
position in its available closing range
Range low $25 Now $32 · 44% Range high $42
vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PBLS
Parabilis Medicines, Inc.
this stock
$3.85B — — — 4.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
79
% held
80.1%
Net QoQ
+99.0M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
32
View
Short & Settlement
Short Interest Rising
Shares short
6.1M
Days to cover
13.3d
Change
+574.5K sh
View
Short Volume
Short vol %
84%
As of
Oct 1, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$3.7K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
46.8%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$6.9M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 16, 2026
This year
7
View
Exempt Offerings
Offering
$178.0M
Filed
Dec 2, 2022
View
Earnings & Events
Webcasts
Last webcast
Sep 16, 2026
View
Investor Relations
Latest news
Parabilis Medicines to Participat…
Published
Sep 1, 2026
View

Performance

5D 20D 120D MTD YTD
PBLS -3.1% -18.2% — -17.2% —
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY -2.4% -18.3% — -16.7% —
Key facts CIK 1657677 CUSIP 698955101 Visit website Investor relations